Replies to post #120380 on Biotech Values

[tony111]

If I recall correctly he lack of interest is due to intro of oral anticoagulants and the low success rate in the anticoagulation arena. However there is a chance we might see it partnered as management stated that there is some interest to make it complementary to oral factor x inhibitors.

[DewDiligence]

[Re: M118]—I guess u have covered it extensively in readme…let me read it. any clue on why it is in limbo for so long?

These entries from the ReadMeFirst can shed some light:

#msg-57237257 Musings on the M118 phase-2b program (1)
#msg-57258943 Musings on the M118 phase-2b program (2)
#msg-56388251 Example of how large ACS trials must be (Cangrelor)
#msg-56881418 With failure of Apixaban, BMY/PFE are potential partners
#msg-56915307 M118 partnership musings